Lithium and Valproate Treatment of Pathological Gambling: A Randomized Single-Blind Study
J Clin Psychiatry 2002;63(7):559-564
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The aim of the present study was
to evaluate the efficacy and safety of lithium and valproate in nonbipolar pathological gamblers.
Method: Forty-two subjects with
DSM-IV-defined pathological gambling entered a
14-week single-blind trial with lithium (N = 23) or
valproate (N = 19). A total of 15 subjects on
lithium treatment and 16 patients on valproate
treatment completed the 14-week protocol.
Results: At the end of the 14-week
treatment period, both the lithium and the valproate
groups showed significant (p < .01) improvement
in mean score on the Yale-Brown Obsessive Compulsive Scale modified for pathological
gambling. This improvement did not significantly differ
between groups. Fourteen (60.9%) of the 23
patients taking lithium and 13 (68.4%) of the 19
patients taking valproate were responders based on
a Clinical Global Impressions-Improvement score of much or very much improved.
Conclusion: Findings from the present
study suggest the efficacy of both lithium carbonate
and valproate in the treatment of pathological gambling. This is the first controlled trial of the
efficacy of mood stabilizers in pathological gambling. A double-blind, placebo-controlled trial
is required to confirm these findings.